SB's Factive not approved

Published: 3-Feb-2001


SmithKline Beecham has received a non-approval letter from the FDA for its antibiotic gemifloxacin mesylate (Factive). Although disappointed with the decision, the company says it still intends to pursue the product.

See more

You may also like

Drug Delivery

Hovione and IDC open intranasal dry powder drug delivery platform for commercial partnerships

Read more
Hovione and IDC have made their integrated intranasal drug delivery platform available for commercial partnerships, combining API development, particle engineering, drug product manufacturing and a single-use nasal dry powder device to accelerate development and scale-up

Trending Articles

  1. SCIEX expands integrated software ecosystem with six mass spectrometry workflow collaborations The firm has announced six software collaborations designed to unify instrument control, data processing and compliance within a single analytical environment, with more partnerships set to be revealed at ASMS 2026
  2. BioNTech to cut up to 1860 jobs and end COVID vaccine production in Germany The German biotech has announced it will cease production at its manufacturing sites in Germany and Singapore in its Q1 earnings report, cutting up to 22% of its workforce in the process as it pivots from COVID-19 vaccines to oncology
  3. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  4. Backed by investments exceeding $1 billion, PCI Pharma Services announces major expansion of US sterile fill-finish and drug-device delivery combination capabilities As pharma manufacturers prioritise US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging
  5. SGS launches GMP-compliant NMR testing for Chinese pharma industry The inspection and certification specialist will now offer nuclear magnetic resonance (NMR) testing for analysis of both drug substances and drug products across China

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Drug Delivery

Hovione and IDC open intranasal dry powder drug delivery platform for commercial partnerships

Hovione and IDC have made their integrated intranasal drug delivery platform available for commercial partnerships, combining API development, particle engineering, drug product manufacturing and a single-use nasal dry powder device to accelerate development and scale-up
Manufacturing

Domino demonstrates an integrated approach to next-generation coding at Interpack 2026

At Interpack 2026, Domino Printing Sciences (Domino) will focus on the key challenges manufacturers face as variable data printing enters a new era shaped by 2D codes, intelligent automation, sustainability, and growing traceability demands. Domino specialists will be available throughout the show to highlight integrated solutions designed to work together on the factory floor – developed in collaboration with key industry partners to help to reduce complexity, risk, and operational friction for manufacturers
Research & Development

From lab to launch: transforming pharmaceutical formulation development with GEA’s CFC Lab Coater

A new generation of continuous film coating technology is giving R&D teams the speed, precision and scalability they need to take products from the laboratory to commercial production without the traditional bottlenecks
Manufacturing

Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target

BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Manufacturing

Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair

Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model
Pharmaceutical

Ardena strengthens executive team to drive its next phase of growth

Ghent, Belgium, 4 May 2026 – Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces the appointments of Ben Ash as Chief Financial Officer and Henny Zijlstra as Chief Commercial Officer. These additions further strengthen Ardena’s executive leadership team as the company continues to scale its operations and commercial reach globally
Manufacturing

Ecolab Life Sciences opens Bioprocessing Applications Lab in Korea to support downstream process development across Asia

New facility serves biopharma manufacturers throughout the region with local access to customer purification studies across Ecolab's Purolite Resin portfolio
Subscribe now